NCT00312026已完成4 期
A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 75
- 主要终点
- The primary efficacy outcome measure is the proportion of patients who achieve a PGA rating of clear (0), almost clear (1), or mild (2) at Day 84.
研究概览
简要总结
This is a Phase IV randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SC efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque psoriasis involving the hands and/or feet who have had no previous exposure to efalizumab. The study will consist of a screening period, a treatment period, and an observation period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) documents
- •Be aged 18 years or older
- •Have chronic (6 months or greater) moderate to severe plaque psoriasis involving the hands and/or feet with or without pustules and with or without psoriasis at other sites
- •Have a PGA rating of moderate (3) or severe (4) for hand and/or foot psoriasis
- •Be a candidate for systemic therapy in the opinion of the investigator
- •Be naive to efalizumab treatment
- •Weigh no more than 125 kg
- •For women of childbearing potential, use a method of contraception acceptable to the investigator to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study and for 6 weeks after the last dose of efalizumab
排除标准
- •Have a history of hypersensitivity to efalizumab or any of its components
- •Are using any excluded therapy
- •Have a history of or ongoing alcohol or illegal drug abuse
- •Have a history of or an ongoing uncontrolled serious bacterial, viral, fungal, or atypical mycobacterial infection. This includes diagnoses that required more than 2 weeks of therapy, such as endocarditis and osteomyelitis, that have been treated in the past 6 months. In addition, if the patient is currently receiving antibiotics, antivirals, or antifungals for an infection or for suppression or prophylaxis for any diagnosis, the patient will be excluded.
- •Have any history of opportunistic infections (e.g., systemic fungal infections, parasites)
- •Are seropositive for hepatitis B antigen, hepatitis C antibody, or human immunodeficiency virus (HIV). Patients will undergo testing during screening, and any patients who are seropositive for hepatitis B antigen, hepatitis C antibody, or HIV will be excluded.
- •Have a history of active tuberculosis or are currently undergoing treatment for tuberculosis. A purified protein derivative (PPD) test or chest x-ray will be performed at the screening visit. Patients with a positive PPD test (not due to BCG vaccination) or chest x-ray will be excluded.
- •Have the presence or history of malignancy within the past 5 years, including lymphoproliferative disorders. Patients with a history of fully resolved basal or squamous cell skin cancer may be enrolled.
- •Are pregnant or lactating women
- •Have a diagnosis of hepatic cirrhosis, regardless of cause or severity
- •Have a history of thrombocytopenia
- •Have a history of hemolytic anemia
- •Have a history of clinically significant anemia
- •Have a WBC count <4,000 cells/uL or >14,000 cells/uL
- •Have a hematocrit (HCT) <30% or a hemoglobin (Hgb) level <11 g/dL
- •Have a platelet count <150,000 cells/uL
- •Have hepatic enzyme levels ≥3 times the upper limit of normal
- •Have a serum creatinine level ≥2 times the upper limit of normal
- •Have been exposed to any experimental drugs or treatments within 30 days or 5 half-lives, whichever is longer, prior to the screening visit
- •Have had any previous exposure to efalizumab
- •Have been vaccinated with a live virus or live bacteria within the 14 days prior to the first dose of efalizumab
- •Have any medical condition that, in the judgment of the investigator, would jeopardize the patient's safety following exposure to study drug (efalizumab or placebo equivalent) or would significantly interfere with the patient's ability to comply with the provisions of this protocol
结局指标
主要结局
The primary efficacy outcome measure is the proportion of patients who achieve a PGA rating of clear (0), almost clear (1), or mild (2) at Day 84.
次要结局
- The change from Day 0 to Day 84 in the following PRO measures: SF 36, PDS, Work Loss Questionnaire
- The proportion of patients who achieve a PGA rating of clear (0) or almost clear (1) at Day 84
- The change from Day 0 in PGA rating (i.e., the number of categories changed) at Day 84
- The proportion of patients who achieve a PGA rating of clear (0), almost clear (1), or mild (2) at Day 42
研究者
相似试验
已完成
4 期
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the ScalpPsoriasisNCT00669214Genentech, Inc.89
已完成
4 期
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With ValbenazineTardive Dyskinesia (TD)NCT03698331Neurocrine Biosciences89
终止
4 期
Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic ImpairmentLiver Cirrhosis, BiliaryNCT03633227Intercept Pharmaceuticals22
终止
1 期
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)NCT04589260Theravance Biopharma72
已完成
4 期
A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease PatientsRespiratory DiseaseNCT03334916Yuhan Corporation223